AstraZeneca, Renovis' exclusive licensee for Cerovive, a drug for stroke victims, has boosted planned enrollment in its Phase III trial to 3,200 patients from 1,700, resulting in a delay of up to one year in regulatory filing. AstraZeneca is adding at least 10 countries to the trial in hopes of increasing the rate of enrollment and cutting the time lag. Release